- ProMIS Neurosciences (PMN) has submitted an Investigational New Drug application for its experimental Alzheimer’s vaccine
- The company submitted its application to the U.S. Food and Drug Administration (FDA) for PMN310 for the treatment of Alzheimer’s Disease
- In preclinical studies, PMN310 showed strong engagement in brain samples from patients with the disease
- ProMIS Neurosciences Inc. (PMN) opened trading at C$6.75 per share
ProMIS Neurosciences (PMN) has submitted an Investigational New Drug application for its experimental Alzheimer’s vaccine.
The company submitted its application to the U.S. Food and Drug Administration (FDA) for PMN310 for the treatment of Alzheimer’s Disease.
PMN310 is designed to be highly selective for toxic oligomers of amyloid-beta (Aß) that are believed to be a major driver of Alzheimer’s Disease. In preclinical studies, PMN310 showed strong engagement in brain samples from patients with the disease.
ProMIS Neurosciences is a biotechnology company focused on therapeutics selectively targeting toxic progression of neurodegenerative diseases.
“This submission is an important milestone for the ProMIS team as we advance our lead compound, PMN310, toward the clinic. We are excited to continue the development of PMN310 to potentially provide a new treatment option with a differentiated profile for patients with Alzheimer’s disease,” said the company’s Chief Executive Officer, Gail Farfel, Ph.D. “We look forward to our transition to a clinical stage company, pending regulatory clearance of the Investigational New Drug application.”
ProMIS Neurosciences, Inc. is a development-stage biotechnology company.
ProMIS Neurosciences Inc. (PMN) opened trading at C$6.75 per share.
